vs
Side-by-side financial comparison of Becton Dickinson (BDX) and Ross Stores (ROST). Click either name above to swap in a different company.
Ross Stores is the larger business by last-quarter revenue ($5.6B vs $5.3B, roughly 1.1× Becton Dickinson). Ross Stores runs the higher net margin — 9.1% vs 7.3%, a 1.9% gap on every dollar of revenue. On growth, Ross Stores posted the faster year-over-year revenue change (10.4% vs -0.4%). Ross Stores produced more free cash flow last quarter ($617.8M vs $549.0M). Over the past eight quarters, Becton Dickinson's revenue compounded faster (2.0% CAGR vs -3.6%).
Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
Ross Stores, Inc., operating under the brand name Ross Dress for Less, is an American chain of discount department stores headquartered in Dublin, California. It is the largest off-price retailer in the U.S.; as of July 2024, Ross operates 1,795 stores in 43 U.S. states, Washington, D.C. Puerto Rico and Guam, covering much of the country, but with no presence in New England and Alaska. The company also operates DD's Discounts, a discount department store chain with over 353 locations across t...
BDX vs ROST — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.3B | $5.6B |
| Net Profit | $382.0M | $511.9M |
| Gross Margin | 45.9% | 28.0% |
| Operating Margin | 10.5% | 11.6% |
| Net Margin | 7.3% | 9.1% |
| Revenue YoY | -0.4% | 10.4% |
| Net Profit YoY | 24.0% | 4.7% |
| EPS (diluted) | $1.34 | $1.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.3B | $5.6B | ||
| Q3 25 | $5.9B | $5.5B | ||
| Q2 25 | $5.5B | $5.0B | ||
| Q1 25 | $5.3B | $5.9B | ||
| Q4 24 | $5.2B | $5.1B | ||
| Q3 24 | $5.4B | $5.3B | ||
| Q2 24 | $5.0B | $4.9B | ||
| Q1 24 | $5.0B | $6.0B |
| Q4 25 | $382.0M | $511.9M | ||
| Q3 25 | $493.0M | $508.0M | ||
| Q2 25 | $574.0M | $479.2M | ||
| Q1 25 | $308.0M | $586.8M | ||
| Q4 24 | $303.0M | $488.8M | ||
| Q3 24 | $400.0M | $527.1M | ||
| Q2 24 | $487.0M | $488.0M | ||
| Q1 24 | $537.0M | $609.7M |
| Q4 25 | 45.9% | 28.0% | ||
| Q3 25 | 47.5% | 27.6% | ||
| Q2 25 | 47.8% | 28.2% | ||
| Q1 25 | 42.8% | 26.5% | ||
| Q4 24 | 43.2% | 28.3% | ||
| Q3 24 | 45.7% | 28.3% | ||
| Q2 24 | 46.2% | 28.1% | ||
| Q1 24 | 45.7% | 27.3% |
| Q4 25 | 10.5% | 11.6% | ||
| Q3 25 | 11.8% | 11.5% | ||
| Q2 25 | 16.0% | 12.2% | ||
| Q1 25 | 10.4% | 12.4% | ||
| Q4 24 | 8.8% | 11.9% | ||
| Q3 24 | 11.4% | 12.5% | ||
| Q2 24 | 12.1% | 12.2% | ||
| Q1 24 | 14.5% | 13.2% |
| Q4 25 | 7.3% | 9.1% | ||
| Q3 25 | 8.4% | 9.2% | ||
| Q2 25 | 10.4% | 9.6% | ||
| Q1 25 | 5.8% | 9.9% | ||
| Q4 24 | 5.9% | 9.6% | ||
| Q3 24 | 7.4% | 10.0% | ||
| Q2 24 | 9.8% | 10.0% | ||
| Q1 24 | 10.6% | 10.1% |
| Q4 25 | $1.34 | $1.58 | ||
| Q3 25 | $1.71 | $1.56 | ||
| Q2 25 | $2.00 | $1.47 | ||
| Q1 25 | $1.07 | $1.79 | ||
| Q4 24 | $1.04 | $1.48 | ||
| Q3 24 | $1.37 | $1.59 | ||
| Q2 24 | $1.68 | $1.46 | ||
| Q1 24 | $1.85 | $1.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $740.0M | $4.1B |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $25.3B | $5.9B |
| Total Assets | $54.8B | $15.4B |
| Debt / EquityLower = less leverage | — | 0.26× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $740.0M | $4.1B | ||
| Q3 25 | $641.0M | $3.8B | ||
| Q2 25 | $735.0M | $3.8B | ||
| Q1 25 | $667.0M | $4.7B | ||
| Q4 24 | $711.0M | $4.3B | ||
| Q3 24 | $1.7B | $4.7B | ||
| Q2 24 | $4.5B | $4.7B | ||
| Q1 24 | $2.3B | $4.9B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.5B |
| Q4 25 | $25.3B | $5.9B | ||
| Q3 25 | $25.4B | $5.7B | ||
| Q2 25 | $25.5B | $5.6B | ||
| Q1 25 | $25.2B | $5.5B | ||
| Q4 24 | $25.2B | $5.3B | ||
| Q3 24 | $25.9B | $5.1B | ||
| Q2 24 | $25.9B | $4.9B | ||
| Q1 24 | $25.6B | $4.9B |
| Q4 25 | $54.8B | $15.4B | ||
| Q3 25 | $55.3B | $14.5B | ||
| Q2 25 | $54.9B | $14.3B | ||
| Q1 25 | $54.5B | $14.9B | ||
| Q4 24 | $54.7B | $14.9B | ||
| Q3 24 | $57.3B | $14.7B | ||
| Q2 24 | $55.6B | $14.5B | ||
| Q1 24 | $54.2B | $14.3B |
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.42× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $657.0M | $827.1M |
| Free Cash FlowOCF − Capex | $549.0M | $617.8M |
| FCF MarginFCF / Revenue | 10.5% | 11.0% |
| Capex IntensityCapex / Revenue | 2.1% | 3.7% |
| Cash ConversionOCF / Net Profit | 1.72× | 1.62× |
| TTM Free Cash FlowTrailing 4 quarters | $2.6B | $2.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $657.0M | $827.1M | ||
| Q3 25 | $1.4B | $668.4M | ||
| Q2 25 | $1.2B | $409.7M | ||
| Q1 25 | $164.0M | $882.6M | ||
| Q4 24 | $693.0M | $513.4M | ||
| Q3 24 | $1.2B | $592.1M | ||
| Q2 24 | $1.3B | $368.9M | ||
| Q1 24 | $514.0M | $948.8M |
| Q4 25 | $549.0M | $617.8M | ||
| Q3 25 | $1.0B | $466.6M | ||
| Q2 25 | $1.0B | $202.3M | ||
| Q1 25 | $35.0M | $676.6M | ||
| Q4 24 | $588.0M | $333.0M | ||
| Q3 24 | $882.0M | $394.6M | ||
| Q2 24 | $1.1B | $232.7M | ||
| Q1 24 | $380.0M | $726.4M |
| Q4 25 | 10.5% | 11.0% | ||
| Q3 25 | 17.0% | 8.4% | ||
| Q2 25 | 19.0% | 4.1% | ||
| Q1 25 | 0.7% | 11.4% | ||
| Q4 24 | 11.4% | 6.6% | ||
| Q3 24 | 16.2% | 7.5% | ||
| Q2 24 | 22.4% | 4.8% | ||
| Q1 24 | 7.5% | 12.1% |
| Q4 25 | 2.1% | 3.7% | ||
| Q3 25 | 6.0% | 3.6% | ||
| Q2 25 | 3.2% | 4.2% | ||
| Q1 25 | 2.4% | 3.5% | ||
| Q4 24 | 2.0% | 3.6% | ||
| Q3 24 | 5.4% | 3.7% | ||
| Q2 24 | 3.6% | 2.8% | ||
| Q1 24 | 2.7% | 3.7% |
| Q4 25 | 1.72× | 1.62× | ||
| Q3 25 | 2.75× | 1.32× | ||
| Q2 25 | 2.12× | 0.85× | ||
| Q1 25 | 0.53× | 1.50× | ||
| Q4 24 | 2.29× | 1.05× | ||
| Q3 24 | 2.94× | 1.12× | ||
| Q2 24 | 2.66× | 0.76× | ||
| Q1 24 | 0.96× | 1.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
ROST
Segment breakdown not available.
